Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Usynova Out-Licenses KRASG12D Inhibitor to AstraZeneca in $419 Million Agreement

publication date: Nov 22, 2023

Shanghai Usynova Biopharma out-licensed global rights for its clinical stage small molecule KRASG12D inhibitor to AstraZeneca in a deal worth up to $419 million. KRAS mutations occur in many cancer types, but KRASG12D is the most common mutation of the group, appearing in 26% of all KRAS mutations. It is prevalent in pancreatic cancer, colorectal cancer, non-small cell lung cancer, among others. Currently, there are no approved therapies that target KRASG12D. Usynova received $24 million upfront and will be eligible for up to $396 million in milestones, plus royalties. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital